ClinicalTrials.gg
CompletedNCT05068466Updated Sep 16, 2022

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707

A Phase 1 interventional study of INCB054707 and Placebo in Healthy Participants, sponsored by Incyte Biosciences Japan GK. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by Incyte Biosciences Japan GK (part of Incyte Corporation) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, sponsor-unblinded, Phase 1 study designed to evaluate the safety, tolerability, and PK of escalating oral doses of INCB054707 in healthy male Japanese participants. Participants in each cohort will be divided into placebo or INCB054707 by a 3:1 INCB054707:placebo random assignment.

02

Conditions studied

  • Healthy Participants

Keywords

  • INCB054707
03

In context

Lead sponsor

Incyte Biosciences Japan GK is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male healthy Japanese adult participants aged 20 to 55 years with a minimum weight of 48 kg.
  • between 18.0 and 30.5 kg/m2.
  • No findings in screening evaluations.
  • Ability to swallow and retain oral medication.
  • Willingness to avoid fathering children

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease.
  • History of rheumatologic/ disorders, except for minor eczema and rosacea.
  • Resting pulse \< 40 bpm or > 100 bpm, confirmed by repeat testing at screening.
  • History or presence of an abnormal before initial dose administration that, in the investigator's opinion, is clinically significant.
  • Presence of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn's disease or chronic pancreatitis).
  • , WBC, , or ANC that is out of the laboratory's range unless considered clinically insignificant by the investigator at screening or check-in.
  • History of within 5 years of screening, with the exception of cured basal cell or squamous cell carcinoma of the skin.
  • Current or recent (within 6 months of screening) clinically significant gastrointestinal disease or surgery (including cholecystectomy, excluding appendectomy) that could affect the absorption of study drug.
  • Any major surgery within 6 months of screening.
  • Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for plasma donation).
  • Blood transfusion within 4 weeks of check-in.
  • Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment
  • Positive test for and known active or infection or risk of reactivation of HBV or HCV.
  • History of alcoholism within 3 months of screening.
  • Positive breath or urine test for ethanol or positive urine screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another medication or current enrollment in another investigational drug study.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with an inducer or inhibitor of , P-gp, or BCRP
  • Current use of prohibited medication
  • Consumption of Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices within 72 hours before the first dose of study drug.
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
  • Known or severe reaction to INCB054707 or any of INCB054707
  • Inability to undergo venipuncture or tolerate venous access.
  • Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
  • History of tobacco- or nicotine-containing product use within 1 month of screening.
  • Use of prescription drugs within 14 days of study drug administration or nonprescription medications/products within 7 days of study drug administration.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study.
  • Positive syphilis test.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    INCB054707 (Dose A)

    Participants will be administered single-dose INCB054707 on Day 1 followed by once daily dose of INCB054707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours

    Drug: INCB054707

  • Experimental
    INCB054707 (Dose B)

    Participants will be administered a single-dose INCB054707 on Day 1 followed by once daily dose of INCB54707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours.

    Drug: INCB054707

  • Placebo comparator
    Placebo (Dose A)

    Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours

    Drug: Placebo

  • Placebo comparator
    Placebo (Dose B)

    Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours

    Drug: Placebo

Interventions

  • Administered Orally

    Also known as: Povorcitinib

  • DrugPlacebo

    Administered Orally

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAE'S)

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

    Time frame: 3 months

  2. Pharmacokinetics Parameter : Cmax of INCB054707

    Maximum Observed Plasma Concentration of INCB054707

    Time frame: 17 Days

  3. Pharmacokinetics Parameter : Cmin of INCB054707

    Minimum Observed Plasma Concentration of INCB054707

    Time frame: 17 Days

  4. Pharmacokinetics Parameter : tmax of INCB054707

    Time to reach maximum plasma concentration of INCB054707

    Time frame: 17 Days

  5. Pharmacokinetics Parameter : AUC(0-t) of INCB054707

    Area Under the concentration- time curve up to the last measurable concentration of INCB054707

    Time frame: 17 Days

  6. Pharmacokinetics Parameter : AUC(0-∞) of INCB054707

    Area Under the Concentration-time Curve From 0 to Infinity of INCB054707

    Time frame: 17 Days

  7. Pharmacokinetics Parameter : AUC(0-tau) of INCB054707

    Area under the single-dose or steady-state plasma concentration-time curve from hour 0 to the end of the dosing period of INCB054707

    Time frame: 17 Days

Secondary outcomes

  1. Pharmacokinetics Parameter : t1/2 of INCB054707

    Pharmacokinetics Parameter : t1/2 of Apparent terminal phase disposition half-life of

    Time frame: 17 Days

  2. Pharmacokinetics Parameter : CL/F of INCB054707

    Oral dose clearance of INCB054707

    Time frame: 17 Days

  3. Pharmacokinetics Parameter : Vz/F of INCB054707

    Apparent oral dose volume of distribution of INCB54707

    Time frame: 17 Days

  4. Pharmacokinetics Parameter : Cavg of INCB054707

    Average plasma concentration at steady state of INCB054707

    Time frame: 17 Days

  5. Pharmacokinetics Parameter : λz of INCB054707

    Apparent terminal-phase disposition rate constant of INCB054707

    Time frame: 17 Days

07

Study locations

1 site
  • Souseikai Fukuoka Mirai Hospital
    Fukuoka, 813-0017, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jan 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 5, 2021
StartActual
Oct 21, 2021
Primary completionActual
Jan 25, 2022
CompletionActual
Jan 25, 2022
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05068466
Responsible party
Sponsor
First posted
Oct 5, 2021
Start date
Oct 21, 2021
Primary completion
Jan 25, 2022
Completion
Jan 25, 2022
Last update
Sep 16, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion